Medical Greens Announces a New Addition to the Dharmanol(TM) Product Line, Dharmanol Citrolene, During November 5th Conferenc...
November 06 2013 - 4:11PM
Marketwired
Medical Greens Announces a New Addition to the Dharmanol(TM)
Product Line, Dharmanol Citrolene, During November 5th Conference
Call
LOS ANGELES, CA--(Marketwired - Nov 6, 2013) - SK3 Group, Inc.'s
(OTC Pink: SKTO) (the "Company") through Mr. David Hoye, developer
of the Dharmanol™ product line for Berkeley Bio-organic Research
Laboratories, announced a new product line Dharmanol™ Citrolene.
The conference call can be heard on the Company's web site,
www.medicalgreens.com.
Mr. Hoye noted the following: "D-Limonene is one of the most
important terpenes found in cannabis/hemp. It has shown significant
anti-cancer properties in a number of studies." Sloan Kettering
Cancer Institute says:
"Animal studies show activity of D-limonene against pancreatic,
stomach, colon, skin, and liver cancers. Data also indicate that
D-limonene slows the promotion/progression stage of
carcinogen-induced tumors in rats. The chemopreventive activity of
D-limonene may be via inhibition of inflammation, oxidative stress
and Ras-signaling as well as the induction of pro-apoptotic state
in a mouse model of skin tumorigenesis."
There are a number of studies showing possible efficacy of
D-limonene against various forms of cancer, utilizing various
mechanisms. 18 of these studies can be found on the Sloan-Kettering
website, which is here:
http://www.mskcc.org/cancer-care/herb/d-limonene
Along with many studies on treating cancer with D-limonene,
other studies have shown that the molecule attaches to the same
receptor sites in humans as benzodiazepines such as Valium and
Xanax. It is suggested that D-limonene stimulates these sites in
the same manner that cannabis stimulates the Anandamide receptors
in the human body. Because the relaxing and depressive effects of
Valium and Xanax are well known, it is thought that natural
chemicals stimulating the same receptors will have similar actions,
but with greatly reduced toxicity.
D-Limonene is thought to be responsible for much of the relaxing
effects of smoked cannabis. These effects are often absent in
refined cannabinoid extracts which have many of the elements of the
plant removed.
A substantial dose of D-limonene is present in Dharmanol
Citrolene. When combined with the CBD, mixed cannabinoid
carboxylates, and the steam-extracted terpene mixture that
compromises the basic Dharmanol formula, D-limonene helps to
provide much of the synergistic "whole plant" effect that many
patients have found to be far superior to refined preparations
where many of the essential elements of the plant are removed and
discarded.
Mr. Hoye concluded, "While the cannabinoids are only to be found
in marijuana / hemp, many of the terpenes are found in a wide
variety of different plants. The D-limonene in Dharmanol ™ is
identical to that in all varieties of cannabis, but is sourced from
other plants. There is 250 mg. of food-grade D-limonene in every
tablet."
FDA Disclaimer
These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat,
cure, or prevent disease. Use only as directed.
About SK3 Group,
Inc. SK3 Group, Inc. is a healthcare logistics and
fulfillment consultancy focused on the delivery of alternative care
and medicine. With seasoned management, breakthrough technology and
best practices, the Company brings standardization and transparency
to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are based on the current plans and
expectations of management and are subject to a number of
uncertainties and risks that could significantly affect the
company's current plans and expectations, as well as future results
of operations and financial condition. A more extensive listing of
risks and factors that may affect the company's business prospects
and cause actual results to differ materially from those described
in the forward-looking statements can be found in the reports and
other documents filed by the company with the Securities and
Exchange Commission. The company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
SK3 Group, Inc. investors@medicalgreens.com Or call 855-868-7577
(Dial 1 for direct IR)
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Apr 2024 to May 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From May 2023 to May 2024